Literature DB >> 11605990

T cell-mediated immune response enhances the severity of myocarditis in secondary cardiotropic virus infection in mice.

C Kishimoto1, Y Hiraoka, H Takada.   

Abstract

In this report, we showed that a previous enterovirus exposure in ordinary mice with normal T cell function, but not in T cell-deficient mice, can influence development of myocardial inflammation with a second virus exposure. Inoculation of 4-week-old male BALB/c-nu/+ (euthymic and normal T cell function) mice with amyocarditic Coxsackie virus B1 (CB1), followed by inoculation 28 days later with myocarditic variant of Coxsackie virus B3 (CB3-m) resulted in more intense myocardial inflammation and injury than was seen in BALB/c-nu/+ inoculated with CB1, followed by inoculation with non-enterovirus, i.e., encephalomyocarditis virus (EMC) or influenza A virus and in age-matched BALB/c-nu/+ mice secondary inoculated with CB3-m alone. In contrast, this phenomenon of the enhancement of the severity of myocarditis by a secondary CB3-m inoculation was not seen in BALB/c-nu/nu (athymic and T cell- deficient) mice. Interestingly, inoculation of BALB/c-nu/+ mice with CB1, followed by inoculation 28 days later with another amyocarditic variant of Coxsackie virus B3 (CB3-o), resulted in more severe myocarditis than was seen in age-matched BALB/c-nu/+ mice secondary inoculated CB3-o alone. Myocardial-activated T cells and elevated serum interleukin-6 were involved in the exacerbation of the disease during the reinfection. T cell-mediated immune responses to a conserved antigenic epitope among the enteroviruses may be involved in the exacerbation of myocardial inflammatory disease during a second enterovirus infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605990     DOI: 10.1007/s003950170025

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  5 in total

1.  One day from dyspnea to death--unsuccessful application of extracorporeal membrane oxygenation in toxoplasma myocarditis following bone marrow transplantation.

Authors:  J Hadem; F Schröder; T Winkler; B Gohrbandt; D Fischer; T Korte; H Drexler
Journal:  Clin Res Cardiol       Date:  2006-06-20       Impact factor: 5.460

2.  Amyocarditic coxsackievirus B3 causes myocarditis in immunocompromised mice.

Authors:  Hitoshi Takada; Chiharu Kishimoto; Masahiko Kurokawa; Yuji Hiraoka
Journal:  Exp Clin Cardiol       Date:  2003

3.  Nucleotide differences of coxsackievirus B3 and chronic myocarditis.

Authors:  Chiharu Kishimoto; Nami Takamatsu; Hiroshi Ochiai; Kagemasa Kuribayashi
Journal:  Heart Vessels       Date:  2014-02-04       Impact factor: 2.037

4.  Immunisation of pigs with a major envelope protein sub-unit vaccine against porcine reproductive and respiratory syndrome virus (PRRSV) results in enhanced clinical disease following experimental challenge.

Authors:  Cinta Prieto; Francisco Javier Martínez-Lobo; Francisco Díez-Fuertes; Patricia Aguilar-Calvo; Isabel Simarro; José María Castro
Journal:  Vet J       Date:  2010-08-14       Impact factor: 2.688

5.  Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice.

Authors:  Elizaveta Padalko; Erik Verbeken; Patrick Matthys; Joeri L Aerts; Erik De Clercq; Johan Neyts
Journal:  BMC Microbiol       Date:  2003-12-21       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.